Private company

RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. is an American pharmaceutical preparations company based in Glen Rock.2

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersGlen Rock, United States2
  • Incorporated inDE3
  • Business address126 Valley Road, Suite C, Glen Rock, Nj 074523
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI54930059K3UXH7XM9O402
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o CORPORATIONS & COMPANIES, INC., 910 FOULK ROAD, SUITE 201, 19803 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 21171882

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$1.6M in 2022−81% since 2016
-$10.0M-$7.5M-$5.0M-$2.5M02016: -$8.5M-$8.5M20162017: -$4.2M-$4.2M2017−50%2018: -$2.2M-$2.2M2018−49%2019: -$1.7M-$1.7M2019−20%2020: -$3.3M-$3.3M2020+91%2021: -$2.6M-$2.6M2021−23%2022: -$1.6M-$1.6M2022−38%
Net income45678910-$2.1M in 2022−77% since 2016
-$10.0M-$7.5M-$5.0M-$2.5M02016: -$9.2M-$9.2M20162017: -$4.3M-$4.3M2017−54%2018: -$2.6M-$2.6M2018−40%2019: -$2.1M-$2.1M2019−18%2020: -$4.3M-$4.3M2020+103%2021: -$3.1M-$3.1M2021−27%2022: -$2.1M-$2.1M2022−33%
Fiscal year20162017201820192020202120222023
Revenue
Research and development$3.2M4$1.5M5$688.3K6$599.3K7$638.3K8$702.0K9$429.5K9
Operating expenses$2.6M9$1.6M9
Operating income-$8.5M4-$4.2M5-$2.2M6-$1.7M7-$3.3M8-$2.6M9-$1.6M9
Interest$586.3K4$102.2K5$136.2K6$404.7K7$545.7K8$724.8K9$603.8K9
Net income-$9.2M4-$4.3M5-$2.6M6-$2.1M7-$4.3M8-$3.1M9-$2.1M10
Earnings per share-$0.049-$0.049
Shares (weighted, basic)88.3M shares9111.3M shares9

Compare RespireRx Pharmaceuticals Inc. with another company

What it owns

What RespireRx Pharmaceuticals Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$889 Dec 31, 2022$1.4K9 Dec 31, 2021−93.7%

Leadership

Who has led RespireRx Pharmaceuticals Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Roger G. Stoll Phd.2006–2008
  2. Mark A. Varney2008–2009
  3. Arnold Lippa2013–2020
  4. James S. J. Manuso2015–2017

Chair

  1. Roger G. Stoll Phd.2009–2012
  2. Arnold Lippa2013–2020

President

  1. Mark A. Varney2008–2009
  2. Arnold Lippa2013–2015
  3. James S. J. Manuso2015–2017

Chief financial officer

  1. Maria S. Messinger2006–2009
  2. Robert N. Weingarten2013–2017
  3. Jeff Eliot Margolis2017–2020
2010201520202025
Board members and other officers (25)

Former names

  • CORTEX PHARMACEUTICALS INC/DE/Dec 22, 1995 to Nov 13, 20153

Timeline

  1. Feb 10, 20258-K Regulation FD disclosure43
  2. Sep 6, 20248-K Bylaws or fiscal year changed44
  3. Aug 2, 20248-K Entered a material agreement45
  4. Jul 8, 20248-K Entered a material agreement; Other events46
  5. May 29, 20248-K Regulation FD disclosure47
  6. Apr 16, 20248-K Entered a material agreement48
  7. Feb 2, 20248-K Entered a material agreement49
  8. Jan 22, 20248-K Entered a material agreement; Executive or director change; Regulation FD disclosure50
  9. Dec 11, 20238-K Entered a material agreement; Regulation FD disclosure51
  10. Oct 12, 20238-K Regulation FD disclosure52
  11. Oct 2, 20238-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure53
  12. Aug 9, 20238-K Entered a material agreement; Regulation FD disclosure54
  13. Aug 20, 2015New chief executive James S. J. Manuso becomes CEO13
  14. Apr 1, 2013New chief executive Arnold Lippa becomes CEO14
  15. Aug 13, 2008New chief executive Mark A. Varney becomes CEO15
  16. Feb 13, 2006New chief executive Roger G. Stoll Phd. becomes CEO16
  17. Feb 10, 1987Founded RespireRx Pharmaceuticals Inc. is founded2

Filings

72 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 42 major events, 21 other. The latest 20:

  1. Nov 14, 2025REVOKED EDGAR
  2. Feb 10, 20258-K EDGAR
  3. Sep 6, 20248-K EDGAR
  4. Aug 2, 20248-K EDGAR
  5. Jul 8, 20248-K EDGAR
  6. May 29, 20248-K EDGAR
  7. Apr 16, 20248-K EDGAR
  8. Apr 1, 2024NT 10-K EDGAR
  9. Feb 2, 20248-K EDGAR
  10. Jan 22, 20248-K EDGAR
  11. Dec 11, 20238-K EDGAR
  12. Nov 17, 202310-Q EDGAR
  13. Nov 14, 2023NT 10-Q EDGAR
  14. Oct 12, 20238-K EDGAR
  15. Oct 2, 20238-K EDGAR
  16. Aug 21, 202310-Q EDGAR
  17. Aug 14, 2023NT 10-Q EDGAR
  18. Aug 9, 20238-K EDGAR
  19. Jun 13, 20238-K EDGAR
  20. May 24, 20238-K EDGAR

The 72 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How RespireRx Pharmaceuticals Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRespireRx Pharmaceuticals Inc.1
  • CIK0000849636
  • Employer ID (EIN)33-03035831
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address126 Valley Road, Suite C, Glen Rock, NJ 074521
  • Phone(201) 444-49471
  • Shares outstanding365,418,647 as of Nov 14, 202312
  • Public float$360.0K as of Jun 30, 20229
  • On EDGAR sinceOct 30, 19951
  • Filings926 in all: 8-K (276), 4 (249), 10-Q (68), 424B3 (34), 3 (29), 10-K (22), NT 10-Q (20), DEF 14A (19)1
    All 60 form types

    10QSB (17), D (14), NT 10-K (12), S-8 (11), S-8 POS (11), CT ORDER (9), UPLOAD (9), 8-K/A (8), SC 13D/A (8), PRE 14A (7), SC 13G (7), 253G2 (6), CORRESP (6), S-3 (6), 10KSB40 (5), 5 (5), SB-2/A (5), EFFECT (4), 10-K/A (3), 10-Q/A (3), 424B5 (3), DEF 14C (3), DEFA14A (3), POS AM (3), SC 13D (3), 1-A/A (2), 10-C (2), 144 (2), 144/A (2), 4/A (2), FWP (2), PRE 14C (2), S-1 (2), S-1/A (2), SB-2 (2), SC 13G/A (2), 1-A (1), 10KSB (1), 10KSB/A (1), 10KSB40/A (1), 25-NSE (1), 253G3 (1), 8-A12B (1), 8-A12B/A (1), 8-A12G (1), PRER14A (1), PRER14C (1), QUALIF (1), REGDEX (1), REVOKED (1), RW (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Apr 17, 2023
    Quarterly report (10-Q) Nov 17, 2023
    Proxy statement (DEF 14A) Oct 30, 2020
    Latest 8-K (8-K) Feb 10, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54